DRUG INTERACTIONS
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Long term studies in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility of Xylocaine have not been conducted.
Pregnancy:
Teratogenic Effects: Pregnancy Category B:
Reproduction studies have been performed in rats at doses up to 6.6 times the maximum human doses and have revealed no significant findings. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
|
OVERDOSAGE
Overdosage of Xylocaine (lidocaine HCl Injection, USP) usually results in signs of central nervous system or cardiovascular toxicity. See ADVERSE REACTIONS.
Should convulsions or signs of respiratory depression and arrest develop, the patency of the airway and adequacy of ventilation must be assured immediately. Should convulsions persist despite ventilatory therapy with oxygen, small increments of anticonvulsive agents may be given intravenously. Examples of such agents include a benzodiazepine (eg, diazepam), an ultrashort-acting barbiturate (eg, thiopental or thiamylal), or a short-acting barbiturate (eg, pentobarbital or secobarbital). If the patient is under general anesthesia, a short-acting muscle relaxant (eg, succinylcholine) may be administered.
Should circulatory depression occur, vasopressors may be used. Should cardiac arrest occur, standard CPR procedures should be instituted.
Dialysis is of negligible value in the treatment of acute overdosage from Xylocaine.
|
CONTRAINDICATIONS
Xylocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. Xylocaine should not be used in patients with Stokes-Adams syndrome, Wolff-Parkinson-White syndrome, or with severe degrees of sinoatrial, atrioventricular, or intraventricular block in the absence of an artificial pacemaker.
|
